Sangamo Therapeutics, Inc.
ENGINEERING AAV
Last updated:
Abstract:
The present disclosure provides methods and compositions to develop AAV capsids with a desired characteristic compared to a natural AAV serotype. These capsids are useful, for example, for the delivery of genome engineering molecules and gene therapy molecules for the treatment of a subject in need thereof.
Status:
Application
Type:
Utility
Filling date:
24 Apr 2020
Issue date:
26 Nov 2020